Grasustek (Pegfilgrastim)

Grasustek is indicated for two primary clinical purposes related to chemotherapy and stem cell collection.

• Prevention of chemotherapy‑induced neutropenia in adult patients receiving myelosuppressive regimens.
• Reduction of the duration of severe neutropenia and associated febrile episodes.
• Support of dose‑dense or dose‑intense chemotherapy protocols by maintaining neutrophil counts.
• Mobilization of peripheral blood stem cells for autologous transplantation when used in combination with chemotherapy.
• Optional use in pediatric patients when clinically justified, following specialist assessment.
• Facilitation of faster recovery of absolute neutrophil count, allowing earlier initiation of subsequent chemotherapy cycles.

The safety profile of pegfilgrastim, the active component of Grasustek, includes a range of observed adverse reactions that are categorized by frequency and clinical significance.

Common

• Bone pain, typically in the limbs or lower back.
• Musculoskeletal discomfort such as arthralgia or myalgia.
• Injection‑site reactions including erythema, swelling, or pruritus.
• Fatigue or mild headache.
• Nausea or mild gastrointestinal upset.
• Fever or chills.

Serious

• Splenic rupture or enlargement.
• Acute respiratory distress syndrome (ARDS) or severe pulmonary toxicity.
• Severe allergic reactions such as anaphylaxis.
• Capillary leak syndrome presenting with hypotension and edema.
• Renal impairment or acute kidney injury.
• Severe thrombocytopenia or coagulation abnormalities.

These events are reported from clinical trials and post‑marketing surveillance.

When prescribing Grasustek, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

• Known hypersensitivity to pegfilgrastim or any excipients.
• History of splenic disorders, including prior rupture or significant enlargement.
• Active infections, especially uncontrolled bacterial or fungal infections.
• Concurrent use of chemotherapy agents that cause profound myelosuppression.
• Pregnancy or breastfeeding status, as safety data are limited.
• Pediatric use only when benefits outweigh potential risks.
• Patients with severe renal or hepatic impairment should be assessed carefully.

Pegfilgrastim may interact with other agents, influencing its efficacy or safety; clinicians should consider these potential interactions when co‑administering medications.

Avoid

• Concomitant use with other colony‑stimulating factors (e.g., filgrastim) due to overlapping mechanisms.
• Live vaccines administered within 2 weeks of pegfilgrastim, as immune response may be altered.
• Concurrent administration with high‑dose steroids may blunt the pharmacodynamic response.

Use with caution

• Chemotherapy agents that cause severe myelosuppression; timing of pegfilgrastim administration should follow recommended intervals.
• Corticosteroids, which may reduce the neutrophil response to pegfilgrastim.
• Anticoagulants, because splenic enlargement could increase bleeding risk.
• Immunosuppressive biologics, which may affect the intended hematopoietic effect.